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Introduction
Nonalcoholic fatty liver disease (NAFLD) represents a range of distinct liver histopathologies ranging from simple steatosis to the more advanced nonalcoholic steatohepatitis (NASH) (Lomonaco et al., 2013) . Often regarded as the hepatic manifestation of the metabolic syndrome, NAFLD is frequently accompanied by metabolic co-morbidities such as obesity, hypertension, dyslipidemia, and hyperglycemia (Ali & Cusi, 2009) . Given its close association with the metabolic syndrome, the prevalence of NAFLD has quickly risen, making it the most common form of chronic liver disease in Western society (Ali & Cusi, 2009 ). Current estimates suggest that the worldwide prevalence of NAFLD ranges between 6%-33% and as high as 50% in certain regions and ethnic populations, whereas NASH is predicted to affect 2.7%-12.2% of the population (Lomonaco et al., 2013; Rahimi & Landaverde, 2013) . Although the mechanisms are not entirely understood, it is generally well accepted that NASH pathogenesis involves several "hits", such as inflammation and oxidative stress, that may act independently or in parallel to drive disease progression (Rahimi & Landaverde, 2013; Lomonaco et al., 2013) .
The role of adipocytes has recently emerged as being instrumental in the development and propagation of inflammation in NASH. In obese states, fat-laden adipocytes are a primary source for the secretion of pro-inflammatory cytokines, including tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and interleukin-1β (IL-1β), which contribute to the increased systemic levels readily observed in NASH (Hotamisligil et al., 1993; Tilg, 2010; Kochi et al., 2014) . The induction of these proinflammatory cytokines within adipose tissue may act in a paracrine fashion by targeting This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 8, 2014 as DOI: 10.1124 at ASPET Journals on June 24, 2017 dmd.aspetjournals.org Downloaded from DMD #60574 5 the liver and propagating the development of NASH pathogenesis (Tilg, 2010) .
Moreover, inflammatory mediators, particularly TNF-α, activate various intracellular signaling cascades and may contribute to the extensive dysregulation of hepatic gene expression profiles observed in the disease (Moylan et al., 2014) .
A recent investigation concerning the global changes of hepatic gene expression profiles in NAFLD revealed extensive changes in the expression of drug metabolizing and membrane transporter genes in NASH (Lake et al., 2011) . Indeed, NASH causes extensive alterations in the regulation of hepatic xenobiotic transporters of both human and rodent models, leading to the functional disruption of acetaminophen, ezetimibe, methotrexate, and arsenic disposition (Hardwick et al., 2012; Hardwick et al., 2011; Canet et al., 2012; Canet et al., 2014; Lickteig et al., 2007) . A common observation in these studies is increased plasma retention coupled to decreased biliary elimination of xenobiotics, suggesting that patients with NASH may represent a unique population of individuals that are at higher risk of experiencing adverse drug reactions. However, little information is currently known regarding the regulation of xenobiotic transporters in distal sites during times of hepatic stress, which may further contribute to altered xenobiotic disposition in hepatic disease states.
In addition to the liver, the kidneys serve as important sites for xenobiotic excretion, and an estimated 30 % of the top 200 prescribed drugs in 2010 are eliminated by renal clearance (Morrissey et al., 2013) . Studies using experimental models of cholestasis have linked liver dysfunction with compensatory responses in the regulation of xenobiotic transporters in the kidneys. Particularly, liver-specific adaptations in xenobiotic transporters occur to restrict further hepatic exposure to toxic levels of bile This article has not been copyedited and formatted. The final version may differ from this version. However, cholestatic stress also results in compensatory adaptations in the expression of renal efflux and uptake transporters that may function to facilitate the secretion of bile acids into the urine Brandoni et al., 2006b) . A recent study confirmed the functional outcome of these adaptations by demonstrating increased cimetidine clearance as a result of kidney Oct2 induction in a rat model of cholestasis (Kurata et al., 2010) . Together, these findings demonstrate the influence of liver dysfunction on kidneyspecific handling of xenobiotics, which may impact their renal secretion.
The purpose of the current study was to investigate the effects of NASH on xenobiotic transporter expression in the kidneys. Several rodent models of NASH were utilized and a comprehensive analysis of kidney mRNA and protein expression profiles across these models was performed. These studies contribute to the hypothesis that during times of hepatic stress, compensatory alterations in kidney function occur to limit the accumulation of endogenous and exogenous compounds in systemic circulation.
Moreover, these findings will change the manner in which we investigate diseasemediated effects on xenobiotic disposition by confirming that physiological adaptations occur in distal tissue sites, which can ultimately contribute to inter-individual variability in response to xenobiotics. This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Materials. Tris-HCl, ethylenediaminetetraacedicacid (EDTA), sodium chloride (NaCl), glycerol, potassium phosphate (KPO 4 ), potassium chloride (KCl), sodium pyrophosphate (decahydrate), and Nonidet P-40 were obtained from Sigma-Aldrich (St. Louis, MO).
Neutral buffered formalin (10%) was obtained from Fisher Scientific (Pittsburgh, PA).
Animals. Eight to ten week old, male, C57BL/6J, B6.Cg-Lep<ob>/J (ob/ob), and B6.BKS(D)-Lepr<db>/J (db/db) mice were obtained from Jackson Laboratories (Bar Harbor, ME). Eight to ten week old, male, Sprague Dawley and Crl:ZUC-Lepr<fa> fatty (fa/fa) rats were obtained from Charles River Laboratories (Wilmington, MA). All animals were acclimated in 12 hour light and dark cycles in a University of Arizona AAALAC-certified animal facility for at least one week prior to initiation of experiments and were given access to standard chow and water ad libitum. Housing and experimental procedures were in accordance with NIH guidelines for the care and use of experimental animals. To model NASH, C57BL/6J mice and Sprague Dawley rats (N=4) were fed either a methionine and choline deficient (MCD) diet (#518810) (Dyets, Inc., Bethlehem, PA), or an atherogenic diet (#D06061401) (Research Diets Inc., New Brunswick, NJ) for 8 weeks. As a control, C57BL/6J mice (N=4) and Sprague Dawley rats (N=4) were fed a methionine and choline re-supplemented diet (#518754) (Dyets, Inc., Bethlehem, PA).
The ob/ob (N=4) and db/db (N=4) mice were fed a MCD diet for 4 weeks to induce NASH. The fa/fa rats were provided a modified high fat diet (#101447) for eight weeks (Dyets, Inc., Bethlehem, PA). The models chosen in this study represent a good spectrum of dietary and genetically altered animal model that have varying pathophysiological and This article has not been copyedited and formatted. The final version may differ from this version. (Canet et al., 2014;  Supplemental Figure 1 ). Moreover, a thorough review highlighting the important features of these models has been published, which the reader is encouraged to visit (Larter & Yeh, 2008) Tissue Harvesting. At the conclusion of dietary feeding, the animals were euthanized via CO 2 asphyxiation. Liver and kidney slices for histolomorphologic examination were placed in 10% neutral-buffered formalin for 24 hours, followed by 70% ethanol. The remaining tissue was snap frozen in liquid nitrogen and stored at -80ºC for future analyses.
Tissue Staining and Evaluations. Paraffin-embedded kidney and liver sections were stained with hematoxylin and eosin (H&E) at the University of Arizona Histology Core.
Kidney sections were evaluated and scored for renal injury. Liver sections were injury scored according to a previously validated NASH scoring method (Kleiner et al., 2005) and the results have been published previously (Canet et al., 2014) .
RNA Purification. Total RNA was extracted and isolated from rat and mouse kidney using RNAzol B reagent (Tel-Test Inc., Friendswood, TX) per the manufacturer's protocol. RNA concentrations were determined using UV spectrophotometry, and the This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Rodent Kidney Pathology in NASH.
Histological assessments were conducted to investigate the effect of NASH on renal morphology. The incidence and severity of kidney pathology (including tubular degeneration, necrosis and regeneration, parenchymal inflammation and glomerular mesangial expansion and/or hypertrophy) are summarized in Table 1 . Across the rat models, a significant increase in overall severity scores was observed in the MCD, atherogenic, and fa/fa animals ( Figure 1C ). Glomerular changes (mesangial expansion and/or hypertrophy) were the most common observation(s) in MCD and atherogenic rats, whereas the fa/fa rats additionally developed parenchymal tubular changes (degeneration/necrosis/regeneration, protein casts) and parenchymal inflammation ( Figure 1A , arrow, inserts; Table 1 ). Similarly, glomerular finding were more common than tubular injury in the mouse models ( Figure 1B , inserts). All mouse groups had increased overall severity scores with the exception of the db/db mice ( Figure 1C and Table 1 ).
Kidney Transporter mRNA Expression in Rodent NASH. mRNA quantification analyses were conducted on renal transporter genes to determine the effect of NASH on their regulation ( Figure 2 and Figure 3 ). The transporters chosen to be investigated in this study represent a group of important proteins that mediate the renal secretion of many xenobiotics, which include pharmaceuticals. Among the uptake transporters investigated in rats, no significant changes in gene expression were noted with the exception of Oat3, which was induced in rat MCD whereas Oatp1 was repressed in the MCD, athero, and fa/fa rat models ( Figure 2A ). In contrast, Oct2 and Oat1 were down-regulated in the This article has not been copyedited and formatted. The final version may differ from this version. Figure 2B ). Like the rats, Oat 3 was significantly induced in the ob/ob and db/db mouse models whereas Oatp1 expression was repressed in the MCD, ob/ob and db/db models and up-regulated in the atherogenic mice ( Figure 2B ).
In contrast to uptake transporters, efflux transporter mRNA was generally upregulated in the rodent models with confirmed-NASH ( Figure 3 , Table 2 ). Mrp2, Mrp4, Bcrp, and Mdr1a (P-gp) genes were all induced in the rat MCD model whereas no changes were observed in the atherogenic and fa/fa rats ( Figure 3A) . Similarly, Mrp2 was induced in the ob/ob mice whereas Mdr1a expression was up-regulated in the MCD, atherogenic, ob/ob and db/db mouse models ( Figure 3B ). No changes were observed in Bcrp expression; however, Mrp4 was induced in the kidney of MCD, ob/ob, and db/db mice ( Figure 3B ).
Kidney Transporter Protein Expression in Rodent NASH.
Protein expression of membrane transporters across rodent models was also investigated and shown in Figure   4 . Consistent with the mRNA analyses, protein expression of the renal efflux transporters Mrp2 and P-gp was induced in the MCD rats ( Figure 4A ). In addition, P-gp expression was induced in the atherogenic rat model. Interestingly, protein expression of Bcrp was down-regulated in the kidney of fa/fa rats ( Figure 4A ). Oatp1a1, Oat1, and Oct1 renal uptake transporter expression was not significantly changed at the protein level in the rat models.
Similar to the rats, efflux transporter expression in the kidney was generally induced at the protein level in mice with NASH ( Figure 4B , Table 2 ). Specifically, Mrp4
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The increase in adverse drug reaction incidents has become a significant health concern worldwide. In the United States, adverse drug reactions (ADRs) have become one of the top-10 causes of death, clearly highlighting the need for more effective pharmacovigilant practices within the healthcare industry (Wooten, 2010; Valente & Murray, 2011) . Many ADRs can be attributed to inter-individual variations in xenobiotic disposition, which may be preventable by identifying factors that contribute to these variations. In addition, recent advances in our understanding of the impact of disease states on xenobiotic pharmacokinetics have helped identify populations that may be at risk for developing ADRs. In particular, diseases that manifest in the liver have gained increased attention given the importance of the liver in mediating xenobiotic metabolism and disposition. Despite previous evidence demonstrating compensatory alterations in the kidney during cholestatic disease, our understanding of how NASH affects renal clearance is lacking and necessitates further investigation.
The purpose of this study was to determine the effects of NASH on the regulation of renal membrane transporters. The use of several models in these investigations allows for a more comprehensive profile that strengthens our findings and allows translating these findings to the human condition more feasible, considering it is currently unknown how the regulation of renal xenobiotic transporters is altered in human NASH. Our results demonstrate that the development of NASH causes significant alterations in the expression of several membrane transporters in the kidneys of various rodent models. In particular, we observe a coordinated up-regulation of Mrp2, Mrp4, and Pgp, suggesting that during times of hepatic stress, the kidneys may compensate by facilitating the renal This article has not been copyedited and formatted. The final version may differ from this version. . Interestingly, our data also show a down-regulation of renal uptake transporter Oatp1a1 expression in NASH, which facilitates the reabsorption of compounds from the renal tubule filtrate, suggesting an overall shift from renal reabsorption to renal secretion of organic anions in NASH.
Furthermore, Mrp2 induction in the kidney has been observed in various rat models of cholestasis (Lee et al., 2001 ) as well as liver ischemia-reperfusion injury (Tanaka et al., 2008) , which is consistent with our findings in the pathologically-confirmed NASH models (MCD, ob/ob, and db/db rodents). function is significantly reduced in NASH whereas Mrp4 is induced leading to a functional shift in the disposition of xenobiotics from bile to plasma (Hardwick et al., 2012; Canet et al., 2014) . The similarity in the changes to hepatic and renal transporter gene expression between cholestasis and NASH is suggestive of a common mechanism mediating these effects. Recent findings show that mice fed an MCD diet develop intrahepatic cholestasis, leading to increased plasma bile acid levels (Wu et al., 2014) . suggesting that bile acids and/or bile constituents may directly regulate Mrp2 gene transcription, possibly through the nuclear receptors farnesoid X receptor and/or pregnane X receptor (Tanaka et al., 2002; Kast et al., 2002) . Together, these results demonstrate that the up-regulation of renal Mrp2 may partially be explained by direct exposure of bile acids to the kidneys due to the development of cholestasis secondary to NASH.
Similar to renal efflux transporters, the expression of Oat3 in the kidney is significantly elevated in rodents with NASH. In particular, we observe an induction of renal Oat3 in the rat MCD as well as the mouse ob/ob and db/db models. In contrast, our data suggests that Oat1 protein expression is not changed, although levels tend to decrease in the ob/ob and db/db models. This is in contrast to studies that suggest Oat1
and Oat3 are commonly coordinated together by various stressors and exogenous sressors (Guo et al., 2013; Ulu et al., 2012; Jin et al., 2012) . However, consistent with our results, similar findings have been reported in experimental models of cholestasis. Chen et al.
demonstrated an induction of Oat3 protein in the kidney whereas Oat1 levels did not change in Eisai hyperbilirubinemic (EHBR) rats, which lack functional Mrp2 and serve as a cholestatic model Liver damage sustained in NASH results in inflammation, and oxidative stress, leading to hepatocellular damage. However, our results suggest that renal injury in the rodent models with NASH is minimal and lack significant evidence of inflammation and oxidative kidney injury. In contrast, the fa/fa, rat model, which failed to develop pathological NASH, had significant renal injury, and yet renal transporter expression in this rodent model did not vary significantly from control rats. Together, these findings suggest that direct renal injury is not a primary factor in membrane transporter regulation in NASH and that the minimal renal injury sustained in rodents with NASH may be due to liver-derived inflammation.
Alternatively, the pathological disturbances that occur in the liver may Further investigation is needed to characterize the differential effects of pro-inflammatory cytokines on hepatic and renal xenobiotic transporter expression in NASH.
The altered regulation of renal transporters in disease states such as cholestasis has resulted in functional disturbances in xenobiotic disposition. Induction of Oct2 in the kidney following bile duct-ligation has been shown to increase cimetidine clearance in rats (Kurata et al., 2010) . Additionally, disturbances in the renal secretion of bromosulphophthalein and p-aminohippurate in rodent cholestatic models were linked to altered transporter function in the kidney (Brandoni & Torres, 2009; Brandoni et al., 2006a) . However, information is lacking regarding the function of membrane transporters in the kidney during diseases such as NASH.
In conclusion, we have demonstrated that rodent models of NASH pathology cause significant alterations to membrane transporter expression in the kidney. In particular, we observe a general induction of renal apical efflux transporters as well as the basolateral uptake transporter, Oat3, whereas Oatp1 expression is significantly downregulated. Together, these data suggest a coordinated regulation of renal membrane transporters in NASH that favors renal secretion. This may serve as an adaptive response mechanism that facilitates the elimination of xenobiotics and bile acids during times of Kidney pathology was assessed via the lesions described below. Values represent the median (range) of N=4 animals and were rounded to next whole number (median of 1.5 is reported as 2). Scoring key: 0-none; 1-minimal (<10% affected); 2-mild (10-25% affected); 3-moderate (25-40% affected); 4-marked (40-50% affected); 5-severe (>50% affected). 
Tubular
